Bio-Rad Laboratories Debt to Equity Ratio 2010-2024 | BIO
Current and historical debt to equity ratio values for Bio-Rad Laboratories (BIO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Bio-Rad Laboratories debt/equity for the three months ending December 31, 2024 was 0.18.
| Bio-Rad Laboratories Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-12-31 | $2.80B | $6.57B | 0.43 |
| 2024-09-30 | $3.12B | $7.49B | 0.42 |
| 2024-06-30 | $2.91B | $6.78B | 0.43 |
| 2024-03-31 | $3.56B | $9.05B | 0.39 |
| 2023-12-31 | $3.56B | $8.74B | 0.41 |
| 2023-09-30 | $3.48B | $8.42B | 0.41 |
| 2023-06-30 | $3.53B | $8.45B | 0.42 |
| 2023-03-31 | $3.90B | $9.76B | 0.40 |
| 2022-12-31 | $3.89B | $9.62B | 0.40 |
| 2022-09-30 | $3.61B | $8.45B | 0.43 |
| 2022-06-30 | $3.76B | $8.92B | 0.42 |
| 2022-03-31 | $4.19B | $10.18B | 0.41 |
| 2021-12-31 | $4.11B | $13.69B | 0.30 |
| 2021-09-30 | $4.62B | $15.33B | 0.30 |
| 2021-06-30 | $3.52B | $11.60B | 0.30 |
| 2021-03-31 | $3.32B | $10.61B | 0.31 |
| 2020-12-31 | $3.09B | $9.88B | 0.31 |
| 2020-09-30 | $3.20B | $8.83B | 0.36 |
| 2020-06-30 | $2.74B | $7.35B | 0.37 |
| 2020-03-31 | $2.39B | $6.29B | 0.38 |
| 2019-12-31 | $2.25B | $5.76B | 0.39 |
| 2019-09-30 | $2.05B | $5.13B | 0.40 |
| 2019-06-30 | $2.16B | $5.49B | 0.39 |
| 2019-03-31 | $2.00B | $4.86B | 0.41 |
| 2018-12-31 | $1.59B | $4.02B | 0.40 |
| 2018-09-30 | $1.82B | $4.90B | 0.37 |
| 2018-06-30 | $1.75B | $4.64B | 0.38 |
| 2018-03-31 | $1.73B | $4.49B | 0.39 |
| 2017-12-31 | $1.34B | $2.93B | 0.46 |
| 2017-09-30 | $1.34B | $2.85B | 0.47 |
| 2017-06-30 | $1.33B | $2.81B | 0.47 |
| 2017-03-31 | $1.25B | $2.71B | 0.46 |
| 2016-12-31 | $1.27B | $2.58B | 0.49 |
| 2016-09-30 | $1.32B | $2.70B | 0.49 |
| 2016-06-30 | $1.26B | $2.62B | 0.48 |
| 2016-03-31 | $1.21B | $2.54B | 0.48 |
| 2015-12-31 | $1.22B | $2.49B | 0.49 |
| 2015-09-30 | $1.24B | $2.43B | 0.51 |
| 2015-06-30 | $1.17B | $2.36B | 0.49 |
| 2015-03-31 | $1.13B | $2.20B | 0.51 |
| 2014-12-31 | $1.16B | $2.19B | 0.53 |
| 2014-09-30 | $1.21B | $2.18B | 0.56 |
| 2014-06-30 | $1.22B | $2.25B | 0.54 |
| 2014-03-31 | $1.21B | $2.23B | 0.54 |
| 2013-12-31 | $1.20B | $2.19B | 0.55 |
| 2013-09-30 | $1.16B | $2.12B | 0.54 |
| 2013-06-30 | $1.41B | $2.07B | 0.68 |
| 2013-03-31 | $1.43B | $2.03B | 0.70 |
| 2012-12-31 | $1.43B | $2.02B | 0.71 |
| 2012-09-30 | $1.37B | $1.94B | 0.71 |
| 2012-06-30 | $1.32B | $1.85B | 0.71 |
| 2012-03-31 | $1.35B | $1.84B | 0.73 |
| 2011-12-31 | $1.35B | $1.74B | 0.78 |
| 2011-09-30 | $1.28B | $1.69B | 0.75 |
| 2011-06-30 | $1.32B | $1.73B | 0.76 |
| 2011-03-31 | $1.30B | $1.61B | 0.80 |
| 2010-12-31 | $1.52B | $1.54B | 0.99 |
| 2010-09-30 | $1.25B | $1.43B | 0.88 |
| 2010-06-30 | $1.22B | $1.30B | 0.94 |
| 2010-03-31 | $1.25B | $1.30B | 0.96 |
| 2009-12-31 | $1.26B | $1.28B | 0.98 |
| 2009-09-30 | $1.25B | $1.23B | 1.02 |
| 2009-06-30 | $1.22B | $1.13B | 1.08 |
| 2009-03-31 | $0.90B | $1.06B | 0.85 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $8.001B | $2.567B |
| Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels outside the United States through subsidiaries which focus on sales, customer service and product distribution. The company operates through two reportable segments - Life Science segment which designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Clinical Diagnostics - This business markets and distributes products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories as well as insurance and forensic testing laboratories. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.977B | 28.52 |
| Boston Scientific (BSX) | United States | $155.488B | 41.98 |
| Stryker (SYK) | United States | $147.446B | 31.70 |
| EssilorLuxottica (ESLOY) | France | $140.780B | 0.00 |
| Medtronic (MDT) | Ireland | $112.764B | 16.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.084B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.818B | 29.12 |
| GE HealthCare Technologies (GEHC) | United States | $42.113B | 20.51 |
| Agilent Technologies (A) | United States | $39.025B | 25.86 |
| ResMed (RMD) | United States | $34.189B | 26.33 |
| Terumo (TRUMY) | Japan | $26.310B | 37.41 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 16.80 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.630B | 12.95 |
| Insulet (PODD) | United States | $20.222B | 86.57 |
| Baxter (BAX) | United States | $17.074B | 12.34 |
| Sunny Optical Technology (SNPTF) | China | $11.331B | 0.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.245B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.513B | 35.65 |
| Demant (WILYY) | Denmark | $7.946B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.621B | 13.06 |
| Prestige Consumer Healthcare (PBH) | United States | $4.200B | 20.05 |
| ICU Medical (ICUI) | United States | $3.995B | 38.03 |
| Envista Holdings (NVST) | United States | $3.693B | 29.38 |
| Perrigo (PRGO) | Ireland | $3.443B | 10.14 |
| Haemonetics (HAE) | United States | $3.188B | 15.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.989B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.921B | 19.69 |
| QuidelOrtho (QDEL) | United States | $2.760B | 23.18 |
| LeMaitre Vascular (LMAT) | United States | $2.269B | 55.15 |
| Neogen (NEOG) | United States | $2.178B | 25.10 |
| AtriCure (ATRC) | United States | $1.914B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.484B | 25.90 |
| InMode (INMD) | Israel | $1.320B | 11.03 |
| BioLife Solutions (BLFS) | United States | $1.276B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.180B | 8.43 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.997B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.938B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.930B | 14.27 |
| Evolus (EOLS) | United States | $0.926B | 0.00 |
| CeriBell (CBLL) | United States | $0.828B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.689B | 0.00 |
| Valneva SE (VALN) | France | $0.643B | 0.00 |
| Omeros (OMER) | United States | $0.557B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.529B | 22.95 |
| Owens & Minor (OMI) | United States | $0.494B | 3.86 |
| Surmodics (SRDX) | United States | $0.492B | 0.00 |
| SNDL (SNDL) | Canada | $0.462B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.459B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.373B | 0.00 |
| ZimVie (ZIMV) | United States | $0.368B | 30.98 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.349B | 0.00 |
| Cerus (CERS) | United States | $0.323B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.321B | 58.60 |
| Viemed Healthcare (VMD) | United States | $0.310B | 29.52 |
| Sanara MedTech (SMTI) | United States | $0.309B | 0.00 |
| Quanterix (QTRX) | United States | $0.292B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Biote (BTMD) | United States | $0.260B | 5.69 |
| Canopy Growth (CGC) | Canada | $0.250B | 0.00 |
| Zynex (ZYXI) | United States | $0.236B | 49.40 |
| Sanuwave Health (SNWV) | United States | $0.231B | 3.24 |
| Brainsway (BWAY) | Israel | $0.212B | 112.80 |
| High Tide (HITI) | Canada | $0.209B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.206B | 15.39 |
| MacroGenics (MGNX) | United States | $0.181B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.174B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.163B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.140B | 17.51 |
| Jin Medical (ZJYL) | China | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.112B | 0.00 |
| Fonar (FONR) | United States | $0.091B | 12.79 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| InterCure (INCR) | Israel | $0.075B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.067B | 0.00 |
| Exagen (XGN) | United States | $0.067B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.063B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.058B | 30.00 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Hongchang (HCIL) | China | $0.051B | 0.00 |
| MariMed (MRMD) | United States | $0.050B | 0.00 |
| United-Guardian (UG) | United States | $0.050B | 14.22 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| INLIF (INLF) | $0.040B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.031B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |